People · Operator
Named in public records as an officer, director or promoter · active 2012–2020 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zymeworks Inc. | — | Biotechnology | Series C | $143.3M | $2.5B | 2012 |
| Kardium Inc. | — | Other Health Care | Series D+ | $117.4M | $2.4B | 2020 |
| Trimel Pharmaceuticals Corp | — | Pharmaceuticals | Series A | $11.0M | $61.9M | 2016 |
Ian Ihnatowycz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ian Ihnatowycz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amos Michelson | 2 | 2 |
| Matthew Hawkins | 1 | 8 |
| Kenneth Galbraith | 1 | 6 |
| David Rosa | 1 | 5 |
| Noel Hall | 1 | 3 |
| Shermaine Tilley | 1 | 3 |
| Nathan Bryson | 1 | 3 |
| David Tucker | 1 | 3 |
| Nick Bedford | 1 | 2 |
| Doug Goertzen | 1 | 2 |
| DION MADSEN | 1 | 2 |
| Tom Rossi | 1 | 2 |
| Kevin Chaplin | 1 | 2 |
| Patrick McCroskey | 1 | 2 |
| Sam Lichtenstein | 1 | 1 |
| Haig Farris | 1 | 1 |
| GORDON NG | 1 | 1 |
| Surjit Dixit | 1 | 1 |
| Armos Michelson | 1 | 1 |
| Manuel Alba-Marquez | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.